DHAKA, Bangladesh
The Bangladeshi medical company on Sunday submitted a request for clinical trials of a locally administered COVID-19 vaccine on the human body.
The Globe Biotech Limited has submitted the application to the Medical Examination Council of Bangladesh, the country’s leading autonomous health regulatory body under the Ministry of Health.
“We are now fully committed to testing the human body after completing the animal tests,” said Dr Asif Mahmud, who heads the Molecular and Cell Biology unit and assistant manager. to Anadolu Group.
It is the only local medical company that has developed a COVID-19 vaccine, called Bongavax.
“It is another milestone for Bangladesh as it is the first time the use of local vaccines in the history of the country,” Mahmud said. “We are eagerly awaiting a final decision with the government, and we hope for the necessary support in this revolutionary development. ”
The company has already signed a memorandum of understanding with the International Center for Diarrhea Disease Research, Bangladesh, based in Dhaka, to conduct human testing of the vaccine.
Meanwhile, a South Asian delta nation of 165 million people is expected to receive at least five million doses of the Oxford-AstraZeneca COVID-19 vaccine from India by 25 January.
Bangladesh will get a total of 30 million views from Bharat Biotech, which makes the vaccine, in six stages.
They also plan to conduct clinical trials of the COVID-19 vaccine with Sinovac Biotech Ltd in China, according to Dr. ABM Khurshid Alam, the country’s head of health.
As many as 527,063 diseases and 7,883 deaths have been diagnosed so far.
The Anadolu Agency website contains only a portion of the news offered to subscribers in the AA News Broadcast System (HAS), and in summary form. Contact us for membership options.